Do Wall Street Analysts Like Vertex Pharmaceuticals Stock?

Boston, Massachusetts-based Vertex Pharmaceuticals Incorporated (VRTX) is a biotechnology company. It focuses on the discovery, development, and commercialization of small-molecule drugs targeting serious diseases. With a market cap of $101.3 billion, Vertex’s operations span the Americas, EMEA, and the Indo-Pacific.

The biotech giant has significantly underperformed the broader market over the past year. VRTX stock prices have plunged 17.7% over the past 52 weeks and 1.9% on a YTD basis, compared to the S&P 500 Index’s ($SPX) 16.1% gain over the past year and 10% surge in 2025.